Haemophilia
Volume 14, Issue 1 pp. 142-144
LETTER TO THE EDITOR

Factor VIII products and inhibitor development: concepts for revision of European regulatory guidelines

B. NEUGEBAUER, 

B. NEUGEBAUER

European Medicines Agency, Canary Wharf, London, UK

Search for more papers by this author
C. DRAI, 

C. DRAI

European Medicines Agency, Canary Wharf, London, UK

Search for more papers by this author
M. HAASE, 

M. HAASE

Paul-Ehrlich-Institut, Langen, Germany

Search for more papers by this author
A. HILGER, 

A. HILGER

Paul-Ehrlich-Institut, Langen, Germany

Search for more papers by this author
B. KELLER-STANISLAWSKI, 

B. KELLER-STANISLAWSKI

Paul-Ehrlich-Institut, Langen, Germany

Search for more papers by this author
P. LAITINEN-PARKKONEN, 

P. LAITINEN-PARKKONEN

Lääkelaitos, Helsinki, Finland

Search for more papers by this author
D. MENTZER, 

D. MENTZER

Paul-Ehrlich-Institut, Langen, Germany

Search for more papers by this author
C. RASMUSSEN, 

C. RASMUSSEN

Lægemiddelstyrelsen, Axel Heides Gade 1, København S, Denmark

Search for more papers by this author
C. RATIGNIER, 

C. RATIGNIER

Agence Française de Sécurité Sanitaire des Produits de Santé, Saint-Denis Cedex, France

Search for more papers by this author
R. SEITZ, 

R. SEITZ

European Medicines Agency, Canary Wharf, London, UK

Search for more papers by this author
First published: 07 December 2007
https://doi.org/10.1111/j.1365-2516.2007.01604.x
Citations: 7
B. Neugebauer, European Medicines Agency, 7 Westferry Circus, Canary Wharf, London E144HB, UK.
Tel.: +44 20 7523 7130; fax: +44 20 7418 8545;
e-mail: [email protected]
First page image

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.